ArticlePloS one2017
Whole-body staging of female patients with recurrent pelvic malignancies: Ultra-fast 18F-FDG PET/MRI compared to 18F-FDG PET/CT and CT.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic Value of FDG PET/MRI in Females With Pelvic Malignancy-A Systematic Review of the Literature.Frontiers in oncology · 2020Pooled it
- Additive value of whole abdomen FDG PET/MRI to standard whole body PET/CT for detection of peritoneal recurrence of ovarian cancer.Journal of ovarian research · 2026Article
- Clinical PET/MR.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026Review
- Review
- Application of PET/MRI in Gynecologic Malignancies.Cancers · 2024Review
- 18F-FDG PET/MRI and 18F-FDG PET/CT for the Management of Gynecological Malignancies: A Comprehensive Review of the Literature.Journal of imaging · 2023Review
- International EANM-SNMMI-ISMRM consensus recommendation for PET/MRI in oncology.European journal of nuclear medicine and molecular imaging · 2023Article
- Breast PET/MRI Hybrid Imaging and Targeted Tracers.Journal of magnetic resonance imaging : JMRI · 2023Review
- Current Update on PET/MRI in Gynecological Malignancies-A Review of the Literature.Current oncology (Toronto, Ont.) · 2023Review
- "Low Dose MR" Dixon Technique for Imaging FDG PET-MR Lymphoma.World journal of nuclear medicine · 2022Article
- A decade of multi-modality PET and MR imaging in abdominal oncology.The British journal of radiology · 2021Review
- Cumulative radiation doses from recurrent PET-CT examinations.The British journal of radiology · 2021Review
- Diagnostic performance of PET/CT and PET/MR in the management of ovarian carcinoma-a literature review.Abdominal radiology (New York) · 2021Review
- Diagnostic efficiency of whole-bodyCancer imaging : the official publication of the International Cancer Imaging Society · 2021Article
- Update on Diagnostic Performance of PET/MRI in Gynecological Malignancies: A Systematic Review and Meta-Analysis.Journal of the Belgian Society of Radiology · 2020Article
- Hybrid PET/MRI in major cancers: a scoping review.European journal of nuclear medicine and molecular imaging · 2019Article
- Asian Society of Gynecologic Oncology International Workshop 2018.Journal of gynecologic oncology · 2019Article
- Comparison ofEuropean journal of nuclear medicine and molecular imaging · 2018Article
- Towards fast whole-body PET/MR: Investigation of PET image quality versus reduced PET acquisition times.PloS one · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the diagnostic feasibility of an ultra-fast 18F-FDG PET/MRI protocol, including T2-w and contrast-enhanced T1-w imaging as well as metabolic assessment (PET) in comparison to 18F-FDG PET/CT and CT for whole-body staging of female patients with suspected recurrence of pelvic malignancies.
methods43 female patients with suspected tumor recurrence were included in this study. Suspicion was based on clinical follow-up and abnormal findings on imaging follow-up. All patients underwent a PET/CT and a subsequent PET/MRI examination. Two readers were asked to evaluate ultra-fast PET/MRI, PET/CT as well as CT datasets of PET/CT separately for suspect lesions regarding lesion count, lesion localization and lesion characterization. Statistical analyses were performed both, on a per-patient and a per-lesion basis.
resultsTumor relapse was present in 38 of the 43 patients. Based on CT readings 25/38 tumor relapses were correctly identified. PET/CT enabled correct identification of 37/38 patients, PET/MRI correctly identified 36 of the 38 patients with recurrent cancer. On a lesion-based analysis PET/MRI enabled the correct detection of more lesions, comprising a lesion-based sensitivity, specificity, positive predictive value, negative predictive value and diagnostic accuracy of 50%, 58%, 76%, 31%, and 53% for CT, 97%, 83%, 93%, 94%, and 92% for PET/CT and 98%, 83%, 94%, 94%, and 94% for PET/MRI, respectively. Mean scan duration of ultra-fast PET/MRI, PET/CT and whole-body CT amounted to 18.5 ± 1 minutes, 18.2 ± 1 minutes and 3.5 minutes, respectively.
conclusionUltra-fast PET/MRI provides equivalent diagnostic performance and examination time when compared to PET/CT and superior diagnostic performance to CT in restaging female patients suspected to have recurrent pelvic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.